Volker Wiebking
Overview
Explore the profile of Volker Wiebking including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
17
Citations
1008
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Dimitri A, Baxter A, Chen G, Hopkins C, Rouin G, Huang H, et al.
Sci Adv
. 2024 Nov;
10(46):eadp9371.
PMID: 39536093
CD8 T cell exhaustion hampers control of cancer and chronic infections and limits chimeric antigen receptor (CAR) T cell efficacy. Targeting in CAR T cells provides therapeutic benefit; however, TET2's...
2.
Hnatiuk A, Bruyneel A, Tailor D, Pandrala M, Dheeraj A, Li W, et al.
Cancer Res
. 2022 Jun;
82(15):2777-2791.
PMID: 35763671
Significance: Newly developed ponatinib analogs retain antitumor efficacy but elicit significantly decreased cardiotoxicity, representing a therapeutic opportunity for safer CML treatment.
3.
Wiebking V, Patterson J, Martin R, Chanda M, Lee C, Srifa W, et al.
Nat Biotechnol
. 2020 Jul;
38(12):1441-1450.
PMID: 32661439
Safeguard mechanisms can ameliorate the potential risks associated with cell therapies but currently rely on the introduction of transgenes. This limits their application owing to immunogenicity or transgene silencing. We...
4.
Wiebking V, Lee C, Mostrel N, Lahiri P, Bak R, Bao G, et al.
Haematologica
. 2020 Apr;
106(3):847-858.
PMID: 32241852
Allogeneic hematopoietic stem cell transplantation is an effective
therapy for high-risk leukemias. In children, graft manipulation
based on the selective removal of aβ T cells and B cells has been...
5.
Majzner R, Rietberg S, Sotillo E, Dong R, Vachharajani V, Labanieh L, et al.
Cancer Discov
. 2020 Mar;
10(5):702-723.
PMID: 32193224
Insufficient reactivity against cells with low antigen density has emerged as an important cause of chimeric antigen receptor (CAR) T-cell resistance. Little is known about factors that modulate the threshold...
6.
Pavel-Dinu M, Wiebking V, Dejene B, Srifa W, Mantri S, Nicolas C, et al.
Nat Commun
. 2019 Dec;
10(1):5624.
PMID: 31796738
An amendment to this paper has been published and can be accessed via a link at the top of the paper.
7.
Martin R, Ikeda K, Cromer M, Uchida N, Nishimura T, Romano R, et al.
Cell Stem Cell
. 2019 May;
24(5):821-828.e5.
PMID: 31051134
Genome editing of human pluripotent stem cells (hPSCs) provides powerful opportunities for in vitro disease modeling, drug discovery, and personalized stem cell-based therapeutics. Currently, only small edits can be engineered...
8.
Pavel-Dinu M, Wiebking V, Dejene B, Srifa W, Mantri S, Nicolas C, et al.
Nat Commun
. 2019 Apr;
10(1):2021.
PMID: 31028274
The original version of this Article omitted the following from the Acknowledgements: "G.B. acknowledges the support from the Cancer Prevention and Research Institute of Texas (RR140081 and RR170721)."This has now...
9.
Pavel-Dinu M, Wiebking V, Dejene B, Srifa W, Mantri S, Nicolas C, et al.
Nat Commun
. 2019 Apr;
10(1):1634.
PMID: 30967552
Gene correction in human long-term hematopoietic stem cells (LT-HSCs) could be an effective therapy for monogenic diseases of the blood and immune system. Here we describe an approach for X-linked...
10.
Kurzay M, Hauck F, Schmid I, Wiebking V, Eichinger A, Jung E, et al.
Haematologica
. 2019 Mar;
104(10):e478-e482.
PMID: 30846493
No abstract available.